Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
about
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Thrombopoietin mimetics for patients with myelodysplastic syndromes.Personalized treatment strategies for elderly patients with myelodysplastic syndromes.Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem.
P2860
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@ast
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@en
type
label
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@ast
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@en
prefLabel
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@ast
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@en
P2093
P50
P921
P1476
Eltrombopag versus placebo for ...... ed, phase 2 superiority trial.
@en
P2093
Agostino Cortelezzi
Alfredo Molteni
Anna Marina Liberati
Antonella Poloni
Aspasia Stamatoullas
Austin Kulasekararaj
Caterina Alati
Enrico Balleari
Esther N Oliva
Flavia Salvi
P304
P356
10.1016/S2352-3026(17)30012-1
P577
2017-02-02T00:00:00Z